COMMUNIQUÉS West-GlobeNewswire

-
ORYZON Continues to Strengthen its Patent Portfolio for Vafidemstat
14/07/2025 -
Real World Data Supports Results of Route 92 Medical’s SUMMIT MAX Clinical Trial
14/07/2025 -
Full Alliance Group Launches Qubitera Holdings, to Develop Quant Blockchain and YAHBEE Wallet for Healthcare and Web3
14/07/2025 -
Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
14/07/2025 -
Salarius Pharmaceuticals Granted Additional Extension to Regain Compliance with Nasdaq’s Stockholders’ Equity Standard
14/07/2025 -
Disc Medicine Appoints Nadim Ahmed to its Board of Directors
14/07/2025 -
Vivos Inc. Submitted the Investigational Device Exemption (IDE) Application for Human Clinical Trials at Mayo Clinic
14/07/2025 -
Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
14/07/2025 -
Borvo EVAC™ System Demonstrates 100% Success Rate in Chronic Subdural Hematoma Clinical Cases Validated Across 5 Medical Centers
14/07/2025 -
NEXGEL and STADA AG Announce Expansion of Partnership for North America
14/07/2025 -
Pineapple, Inc. to Launch Real-World Asset Token Designed to Monetize Intellectual Property
14/07/2025 -
BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis
14/07/2025 -
Dr. Anosh Ahmed Foundation Launches Chicago-Based Initiative to Support Families of Fallen FBI Agents and Law Enforcement Officers
14/07/2025 -
Positive Response Fuels New Efforts by Dr. Anosh Ahmed and the Anosh Inc. Foundation to Support Families of Fallen Officers and FBI Agents
14/07/2025 -
Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery
14/07/2025 -
Ascentage Pharma Announces Proposed Top-Up Placement
14/07/2025 -
Anavar for Women: Exploring the Rise of Anvarol Performance Supplement Among Female Bodybuilders and Athletes From CrazyBulk
14/07/2025 -
NTG Nordic Transport Group A/S - H1 2025 Conference Call
14/07/2025 -
OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025
14/07/2025
Pages